Control/Lesion Type
|
Methylation Status
|
---|
RB1
|
CDH1
|
---|
HPV+, n (%)*
|
EBV+, n (%)
|
HPV and EBV+, n (%)
|
HPV and EBV-, n (%)
|
HPV+, n (%)
|
EBV+, n (%)**
|
HPV and EBV+, n (%)
|
HPV and EBV-, n (%)
|
---|
Control (n = 15)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
1 (20.0)
|
1 (25.0)
|
0 (0.0)
|
0 (0.0)
|
1 (20.0)
|
LSIL (n = 17)
|
1 (9.1)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
2 (15.3)
|
0 (0.0)
|
0 (0.0)
|
HSIL (n = 15)
|
4 (50.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
4 (50.0)
|
2 (28.6)
|
2 (50.0)
|
0 (0.0)
|
Cancer (n = 18)
|
7 (50.0)
|
7 (63.6)
|
6 (60.0)
|
1 (33.3)
|
4 (28.6)
|
5 (45.5)
|
4 (40.0)
|
1 (33.3)
|
Total (n = 65)
|
12 (32.4)
|
7 (17.9)
|
6 (25.0)
|
2 (15.3)
|
9 (24.3)
|
9 (23.1)
|
6 (25.0)
|
2 (15.3)
|
-
*
p
= 0.0421 (LSIL
versus
Cancer).
-
**
p
= 0.1819 (LSIL
versus
Cancer).
- +, presence; -, absence; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions.